A Timeline of US Biosimilar Adalimumab Launch Dates

AbbVie has struck agreements with multiple developers over biosimilar adalimumab, forestalling US market entry until 2023. Here's when each product could potentially reach US patients.

AbbVie has struck agreements with multiple developers over biosimilar adalimumab, forestalling US market entry until 2023. Here's when each product could reach US patients.

Related Content:

BusinessRheumatology
Overcoming Challenges to Improve Access and Reduce Costs
Challenges, Obstacles, and Future Directions for Anti-TNF Biosimilars in IBD
Skyrizi Overtakes Humira: “Product Hopping” Leaves Biosimilar Market in Limbo